Is venetoclax appropriate for relapsed CLL patients?
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Gareth Morgan et al.
BCR inhibitors improving CLL patient outcomes
Targeted treatments for AML: the revolution
Overview of the RATIFY study: midostaurin combination therapy for AML